What to know about new advice on prostate cancer test

April 11, 2017 by Lindsey Tanner

Should middle-aged men get routine blood tests for prostate cancer? An influential health panel that once said no now says maybe. It says certain men may benefit as long as they understand the potential harms.

Some key things to know about the U.S. Preventive Services Task Force's draft recommendations :

Q. What's the new advice?

A: Men should decide for themselves if they want to get tested, the panel says. But first, they should have a talk with their doctor about the pros and the cons of the PSA test. That applies to men aged 55 to 69 of average risk for as well as those with higher odds, including blacks and men with a of the disease. Those 70 and older shouldn't get screened.

Q: Is this a significant change?

A: Yes, the panel in 2012 decided men shouldn't get tested, saying there was no evidence that benefits outweigh harms that can result from overdiagnosis and overtreatment. In 2008, the group said there was too little evidence to make any kind of recommendation for younger men but said those 75 and older shouldn't be screened.

Q: Why the change?

A: The panel says there's now some evidence that screening can save lives. New research shows testing men aged 55 to 69 may slightly reduce their chances of dying from . There's also newer evidence that "active surveillance," which involves repeated PSA testing and close monitoring, can help men diagnosed with cancer avoid harsh treatment or at least delay it.

Q: What is PSA screening?

A: It's a simple blood test for a specific protein. Elevated levels may be sign of cancer, but can be caused by less serious conditions, like an enlarged prostate or an infection. The goal is to find cancer at an early, treatable stage. Biopsies confirm suspicious results. The U.S. Food and Drug Administration approved the test for screening in 1994.

Q: How could a blood test be harmful?

A: Prostate cancer usually grows too slowly to be lethal; most affected men will die of other causes and never experience symptoms. Positive tests may lead to treatment for something that isn't dangerous. Treatment often involves radiation or surgery, which can cause incontinence and impotence.

Q: How common is prostate cancer?

A: This year, more than 1 million men will be diagnosed worldwide including about 160,000 Americans; more than 26,000 U.S. men will die of the disease. Most men are diagnosed after age 60.

Q: What challenges remain?

A: Experts acknowledge that the PSA isn't perfect. Researchers are seeking a more accurate way to detect prostate cancer and agree on the need for technology to identify which early-stage tumors will grow to become deadly.

Q: What is the ?

A: The group is an independent panel of 16 doctors and other health experts who evaluate medical studies on screenings and other preventive medicine. Their recommendations influence U.S. government policy, and private insurers' coverage decisions. Medicaid and many insurers cover PSA screening.

Q: What do other groups recommend?

A: Most other leading groups agree that decisions should be made by patients after doctors tell them of all the pros and cons. The American Cancer Society says start PSA discussions at age 50 for men at average risk; at age 40 for men with a strong family history and age 45 for black men.

The American Urological Association's recommendations cover ages 55 to 69 and say screening should be considered at earlier ages for blacks and men with a family history.

The European Association of Urology says should be offered to well-informed men over 50 or over 45 for blacks and those with a family history.

Explore further: Prostate cancer tests are now OK with US panel, with caveats

Related Stories

Prostate cancer tests are now OK with US panel, with caveats

April 11, 2017
An influential U.S. government advisory panel is dropping its opposition to routine prostate cancer screening in favor of letting men decide for themselves after talking with their doctor.

Are men with a family history of prostate cancer eligible for active surveillance?

April 6, 2017
Active surveillance—careful monitoring to determine if or when a cancer warrants treatment—is an increasingly prevalent choice for prostate cancer, but it's unclear if the strategy is appropriate for men with a family ...

Prostate cancer treatment rates drop, reflecting change in screening recommendations

January 9, 2017
As some national guidelines now recommend against routine prostate cancer screening, the overall rate of men receiving treatment for the disease declined 42 percent, a new study finds.

As routine screenings drop, prostate cancer on rise in older men

January 4, 2017
The incidence of metastatic prostate cancer in older men is rising after reaching an all-time low in 2011, according to new research from Weill Cornell Medicine and NewYork-Presbyterian investigators.

PSA for prostate screening unaffected by changes in screening guidelines

October 6, 2016
Controversy over prostate cancer screening guidelines that discourage use of PSA tests did not significantly reduce use of the test, a five-year review of more than 275,000 visits at UT Southwestern Medical Center showed.

Recommendation against PSA test too drastic: WU expert

May 22, 2012
(Medical Xpress) -- A new recommendation issued today by the U.S. Preventive Services Task Force against routine PSA testing for healthy men age 50 and older goes too far, says a prostate cancer expert at the Siteman Cancer ...

Recommended for you

Student develops microfluidics device to help scientists identify early genetic markers of cancer

October 16, 2018
As anyone who has played "Where's Waldo" knows, searching for a single item in a landscape filled with a mélange of characters and objects can be a challenge. Chrissy O'Keefe, a Ph.D. student in the Department of Biomedical ...

A bad influence—the interplay between tumor cells and immune cells

October 16, 2018
Research at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) yielded new insights into the environment surrounding different types of lung tumors, and described how these complex cell ecosystems may in turn ...

Technique to 'listen' to a patient's brain during tumour surgery

October 16, 2018
Surgeons could soon eavesdrop on a patient's brain activity during surgery to remove their brain tumour, helping improve the accuracy of the operation and reduce the risk of impairing brain function.

Researchers elucidate roles of TP63 and SOX2 in squamous cell cancer progression

October 16, 2018
Squamous cell carcinomas (SCCs) are aggressive malignancies arising from the squamous epithelium of various organs, such as the esophagus, head and neck, lungs, and skin. Previous studies have demonstrated that two master ...

Function of neutrophils during tumor progression unraveled

October 15, 2018
Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and ...

Delving where few others have gone, leukemia researchers open new path

October 15, 2018
A Wilmot Cancer Institute study uncovers how a single gene could be at fault in acute myeloid leukemia (AML), one of the deadliest cancers. The breakthrough gives researchers renewed hope that a gene-targeted therapy could ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.